Targeting B-cell maturation antigen in multiple myeloma

Immunotherapy

Volumn 7, Issue 11, 2015, Pages 1187-1199

  Tai, Yu Tzu ^a   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

ADC; antibody drug conjugate; B cell maturation antigen; BCMA; BM; bone marrow; CAR expressing T cells; CAR T; chimeric antigen receptor; Fc engineered therapeutic antibody; microenvironment; MM; multiple myeloma; targeted immunotherapy

Indexed keywords

ANTIBODY CONJUGATE; B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; GSK 2857916; OBINUTUZUMAB; UNCLASSIFIED DRUG; VEDOTIN; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; MONOMETHYL AURISTATIN F; OLIGOPEPTIDE; TNFRSF17 PROTEIN, HUMAN; TUMOR ANTIGEN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CHROMATIN IMMUNOPRECIPITATION; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG MECHANISM; DRUG TARGETING; HUMAN; IMMUNOGENICITY; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; PROTEIN ENGINEERING; TRANSPLANTATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; B-CELL MATURATION ANTIGEN; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; OLIGOPEPTIDES; PROTEIN ENGINEERING; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84948188408     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.77     Document Type: Review

References (75)

1. Dimopoulos MA, Richardson PG, Moreau P, Anderson KC. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat. Rev. Clin. Oncol. 12(1), 42-54 (2015).
2. Richardson PG, Mitsiades C. Bortezomib: proteasome inhibition as an effective anticancer therapy. Future Oncol. 1(2), 161-171 (2005).
3. Teicher BA, Anderson KC. CCR 20th anniversary commentary: In the beginning, there was PS-341. Clin. Cancer Res. 21(5), 939-941 (2015).
4. Dimopoulos MA, Terpos E. Hematology: first-line bortezomib benefits patients with multiple myeloma. Nat. Rev. Clin. Oncol. 6(12), 683-685 (2009).
5. Musto P, D'Auria F, Pietrantuono G et al. First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective. Curr. Drug Targets 10(10), 906-922 (2009).
6. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J. Clin. Invest. 122(10), 3456-3463 (2012).
7. Shaffer AL, Emre NC, Lamy L et al. IRF4 addiction in multiple myeloma. Nature 454(7201), 226-231 (2008).
8. Hurt EM, Wiestner A, Rosenwald A et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 5(2), 191-199 (2004).
9. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. Cancer 7(8), 585-598 (2007).
10. Tai YT, Anderson KC. Principles of pathway directed therapy. In: Myeloma: Pathology, Diagnosis & Management. Schey SA, Yong KL, Marcus R, Anderson KC (Eds). Cambridge University Press, NY, USA, 110-120 (2014).
11. Elgueta R, de Vries VC, Noelle RJ. The immortality of humoral immunity. Immunol. Rev. 236, 139-150 (2010).
12. Chiu A, Xu W, He B et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood 109(2), 729-739 (2007).
13. Avery DT, Kalled SL, Ellyard JI et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J. Clin. Invest. 112(2), 286-297 (2003).
14. O'Connor BP, Raman VS, Erickson LD et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199(1), 91-98 (2004).
15. Darce JR, Arendt BK, Chang SK, Jelinek DF. Divergent effects of BAFF on human memory B cell differentiation into Ig-secreting cells. J. Immunol. 178(9), 5612-5622 (2007).
16. Xu S, Lam KP. B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol. Cell. Biol. 21(12), 4067-4074 (2001).
17. Claudio JO, Masih-Khan E, Tang H et al. A molecular compendium of genes expressed in multiple myeloma. Blood 100(6), 2175-2186 (2002).
18. Tai YT, Li XF, Breitkreutz I et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 66(13), 6675-6682 (2006).
19. Moreaux J, Legouffe E, Jourdan E et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 103(8), 3148-3157 (2004).
20. Moreaux J, Cremer FW, Reme T et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 106(3), 1021-1030 (2005).
21. Yaccoby S, Pennisi A, Li X et al. Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia 22(2), 406-413 (2008).
22. Carpenter RO, Evbuomwan MO, Pittaluga S et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 19(8), 2048-2060 (2013).
23. Maus MV, June CH. Zoom zoom: racing CARs for Multiple Myeloma. Clin. Cancer Res. 19(8), 1917-1919 (2013).
24. Tai YT, Mayes PA, Acharya C et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 123(20), 3128-3138 (2014).
25. Frigyesi I, Adolfsson J, Ali M et al. Robust isolation of malignant plasma cells in multiple myeloma. Blood 123(9), 1336-1340 (2014).
26. Chauhan D, Singh AV, Brahmandam M et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell 16(4), 309-323 (2009).
27. Bellucci R, Alyea EP, Chiaretti S et al. Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood 105(10), 3945-3950 (2005).
28. Neri P, Kumar S, Fulciniti MT et al. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin. Cancer Res. 13(19), 5903-5909 (2007).
29. Tai YT, Acharya C, Zhong MY et al. Constitutive B-Cell maturation antigen (BCMA) activation in human multiple myeloma cells promotes myeloma cell growth and survival in the bone marrow microenvironment via upregulated MCL-1 and NFB signalling. ASH Annual Meeting Abstracts 681 (2013).
30. Rennert P, Schneider P, Cachero TG et al. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J. Exp. Med. 192(11), 1677-1684 (2000).
31. Moreaux J, Sprynski AC, Dillon SR et al. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop. Eur. J. Haematol. 83(2), 119-129 (2009).
32. Sanchez E, Li M, Kitto A et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br. J. Haematol. 158(6), 727-738 (2012).
33. Lonial S, Vij R, Harousseau J-L et al. Phase 1/2 study of elotuzumab in combination with lenalidomide and low dose dexamethasone in relapsed or refractory multiple myeloma: interim results. Blood 114, 432 (2009).
34. Laubach JP, Voorhees PM, Hassoun H, Jakubowiak A, Lonial S, Richardson PG. Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Rev. Hematol. 7(1), 97-111 (2014).
35. Laubach JP, Tai YT, Richardson PG, Anderson KC. Daratumumab granted breakthrough drug status. Expert Opin. Investig. Drugs 23(4), 445-452 (2014).
36. Deckert J, Wetzel MC, Bartle LM et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin. Cancer Res. 20(17), 4574-4583 (2014).
37. Lutz RJ, Whiteman KR. Antibody-maytansinoid conjugates for the treatment of myeloma. mAbs 1(6), 548-551 (2009).
38. Berdeja JG. Lorvotuzumab mertansine: antibody-drugconjugate for CD56+ multiple myeloma. Front. Biosci. (Landmark Ed.) 19, 163-170 (2014).
39. Ikeda H, Hideshima T, Fulciniti M et al. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin. Cancer Res. 15(12), 4028-4037 (2009).
40. Kelly KR, Chanan-Khan A, Heffner LT et al. Indatuximab Ravtansine (BT062) in combination with lenalidomide and low dose dexamethasone in patients with relapsed and/or refractory multiple myeloma: clinical activity in patients already exposed to lenalidomide and bortezomib. Blood 122, Abstract 4736 (2014).
41. Sapra P, Stein R, Pickett J et al. Anti-CD74 antibodydoxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin. Cancer Res. 11(14), 5257-5264 (2005).
42. Tai YT, Horton HM, Kong SY et al. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood 119(9), 2074-2082 (2012).
43. Ryan MC, Hering M, Peckham D et al. Antibody targeting of B-cell maturation antigen on malignant plasma cells. Mol. Cancer Ther. 6(11), 3009-3018 (2007).
44. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr. Opin. Chem. Biol. 14(4), 529-537 (2010).
45. Sutherland MS, Sanderson RJ, Gordon KA et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J. Biol. Chem. 281(15), 10540-10547 (2006).
46. Tai YT, Dillon M, Song W et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112(4), 1329-1337 (2008).
47. de Weers M, Tai YT, van der Veer MS et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 186(3), 1840-1848 (2011).
48. Gill S, June CH. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol. Rev. 263(1), 68-89 (2015).
49. Kochenderfer JN, Dudley ME, Kassim SH et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33(6), 540-549 (2015).
50. June CH, Riddell SR, Schumacher TN. Adoptive cellular therapy: a race to the finish line. Sci. Transl. Med. 7(280), 280ps287 (2015).
51. Grupp SA, Kalos M, Barrett D et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368(16), 1509-1518 (2013).
52. Kochenderfer JN, Wilson WH, Janik JE et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116(20), 4099-4102 (2010).
53. Jiang H, Zhang W, Shang P et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol. Oncol. 8(2), 297-310 (2014).
54. Chu J, Deng Y, Benson DM et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance invitro and in vivo antitumor activity against human multiple myeloma. Leukemia 28(4), 917-927 (2014).
55. Maus MV, June CH. CARTs on the road for myeloma. Clin. Cancer Res. 20(15), 3899-3901 (2014).
56. Chu J, He S, Deng Y et al. Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. Clin. Cancer Res. 20(15), 3989-4000 (2014).
57. Gross JA, Johnston J, Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404(6781), 995-999 (2000).
58. Raje N, Roodman GD. Advances in the biology and treatment of bone disease in multiple myeloma. Clin. Cancer Res. 17(6), 1278-1286 (2011).
59. Gatto B. Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells. Curr. Opin. Investig. Drugs 9(11), 1216-1227 (2008).
60. Rossi JF, Moreaux J, Hose D et al. Atacicept in relapsed/refractory multiple myeloma or active Waldenstrom's macroglobulinemia: a Phase I study. Br. J. Cancer 101(7), 1051-1058 (2009).
61. Tai YT, Acharya C, An G et al. A novel anti-a proliferationinducing ligand hAPRIL.01A monoclonal antibody targets multiple myeloma cells in the bone marrow microenvironment. ASH Annual Meeting Abstracts 2098 (2014).
62. Oak E, Bartlett NL. Blinatumomab for the treatment of B-cell lymphoma. Expert Opin. Investig. Drugs 24(5), 715-724 (2015).
63. Ramadoss NS, Schulman AD, Choi SH et al. An anti-B cell maturation antigen bispecific antibody for multiple myeloma. J. Am. Chem. Soc. 137(16), 5288-5291 (2015).
64. Sanford M. Blinatumomab: first global approval. Drugs 75(3), 321-327 (2015).
65. Korde N, Carlsten M, Lee MJ et al. A Phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica 99(6), e81-83 (2014).
66. Benson DM, Hofmeister CC, Padmanabhan S et al. A Phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 120(22), 4324-4333 (2012).
67. Benson DM, Bakan CE, Zhang S et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood 118(24), 6387-6391 (2011).
68. Alici E. IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers. Curr. Opin. Mol. Ther. 12(6), 724-733 (2010).
69. Flores-Montero J, de Tute R, Paiva B et al. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin. Cytom. (2015).
70. Coles SJ, Wang EC, Man S et al. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 25(5), 792-799 (2011).
71. Aref S, Azmy E, El-Gilany AH. Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma. Hematol. Oncol. doi:10.1002/hon.2206 (2015) (Epub ahead of print).
72. Moreaux J, Hose D, Reme T et al. CD200 is a new prognostic factor in multiple myeloma. Blood 108(13), 4194-4197 (2006).
73. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PDL1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin. Cancer Res. 19(19), 5300-5309 (2013).
74. Azijli K, Stelloo E, Peters GJ, AJ VDE. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies. Anticancer Res. 34(4), 1493-1505 (2014).
75. Rosenblatt J, Glotzbecker B, Mills H et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J. Immunother. 34(5), 409-418 (2011).